ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a ...
Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of ...
Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $59.9 million in its fourth quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 28 ...
Q4 2024 Earnings Call Transcript March 13, 2025 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, ...
Citizens upgraded Allogene Therapeutics (NASDAQ:ALLO) to Market Perform from Market Underperform on Friday, establishing a $5 ...
In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...
Pattinson has racked up an impressive filmography full of fascinating directors who have allowed him to evolve into a ...